LZTS1 downregulation confers paclitaxel resistance and is associated with worse prognosis in breast cancer

Oncotarget

Volumn 5, Issue 4, 2014, Pages 970-977

  Lovat, Francesca ^a   Ishii, Hideshi ^b   Schiappacassi, Monica ^c   Fassan, Matteo ^a,d   Barbareschi, Mattia ^e   Galligioni, Enzo ^e   Gasparini, Pierluigi ^a   Baldassarre, Gustavo ^c   Croce, Carlo M ^a   Vecchione, Andrea ^a,f  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OSAKA UNIVERSITY   (Japan)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^d UNIVERSITY AND HOSPITAL TRUST OF VERONA   (Italy)

^e SANTA CHIARA HOSPITAL   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Breast cancer; Lzts1 Fez1; Taxanes

Indexed keywords

ANTHRACYCLINE DERIVATIVE; LEUCINE ZIPPER TUMOR SUPPRESSOR 1 PROTEIN; PACLITAXEL; TRASTUZUMAB; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; LZTS1 PROTEIN, HUMAN; SMALL INTERFERING RNA; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MICROTUBULE; OVERALL SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ANIMAL; BIOSYNTHESIS; BREAST NEOPLASMS; DRUG RESISTANCE; GENE SILENCING; GENETICS; MCF 7 CELL LINE; METABOLISM; MIDDLE AGED; MOUSE; PROGNOSIS; TUMOR RECURRENCE;

ANIMALS; BREAST NEOPLASMS; DNA-BINDING PROTEINS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE SILENCING; HUMANS; IMMUNOHISTOCHEMISTRY; MCF-7 CELLS; MICE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; PROGNOSIS; RNA, SMALL INTERFERING; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84897469173     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1630     Document Type: Article

References (33)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer Journal international du cancer. 2010; 127(12):2893-2917.
2. Cardoso F, Senkus-Konefka E, Fallowfield L, Costa A and Castiglione M. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2010; 21 Suppl 5:v15-19.
3. De Laurentiis M, Cancello G, D'Agostino D, Giuliano M, Giordano A, Montagna E, Lauria R, Forestieri V, Esposito A, Silvestro L, Pennacchio R, Criscitiello C, Montanino A, Limite G, Bianco AR and De Placido S. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2008; 26(1):44-53.
4. Kumar N. Taxol-induced polymerization of purified tubulin. Mechanism of action. The Journal of biological chemistry. 1981; 256(20):10435-10441.
5. Schiff PB and Horwitz SB. Taxol assembles tubulin in the absence of exogenous guanosine 5'-triphosphate or microtubule-associated proteins. Biochemistry. 1981; 20(11):3247-3252.
6. Rowinsky EK and Donehower RC. Paclitaxel (taxol). The New England journal of medicine. 1995; 332(15):1004-1014.
7. Jordan MA and Wilson L. Microtubules as a target for anticancer drugs. Nature reviews Cancer. 2004; 4(4):253-265.
8. Verma RP and Hansch C. Taxane analogues against breast cancer: a quantitative structure-activity relationship study. ChemMedChem. 2008; 3(4):642-652.
9. Robinson WR, Davis N and Rogers AS. Paclitaxel maintenance chemotherapy following intraperitoneal chemotherapy for ovarian cancer. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society. 2008; 18(5):891-895.
10. Choong NW, Vokes EE, Haraf DJ, Tothy PK, Ferguson MK, Kasza K, Rudin CM, Hoffman PC, Krauss SA, Szeto L and Mauer AM. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2008; 3(1):59-67.
11. Agarwala SS, Cano E, Heron DE, Johnson J, Myers E, Sandulache V, Bahri S, Ferris R, Wang Y and Argiris A. Long-term outcomes with concurrent carboplatin, paclitaxel and radiation therapy for locally advanced, inoperable head and neck cancer. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2007; 18(7):1224-1229.
12. Samadi N, Gaetano C, Goping IS and Brindley DN. Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis. Oncogene. 2009; 28(7):1028-1039.
13. Estevez LG and Gradishar WJ. Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2004; 10(10):3249-3261.
14. Ishii H, Baffa R, Numata SI, Murakumo Y, Rattan S, Inoue H, Mori M, Fidanza V, Alder H and Croce CM. The FEZ1 gene at chromosome 8p22 encodes a leucine-zipper protein, and its expression is altered in multiple human tumors. Proceedings of the National Academy of Sciences of the United States of America. 1999; 96(7):3928-3933.
15. Cabeza-Arvelaiz Y, Sepulveda JL, Lebovitz RM, Thompson TC and Chinault AC. Functional identification of LZTS1 as a candidate prostate tumor suppressor gene on human chromosome 8p22. Oncogene. 2001; 20(31):4169-4179.
16. Vecchione A, Ishii H, Shiao YH, Trapasso F, Rugge M, Tamburrino JF, Murakumo Y, Alder H, Croce CM and Baffa R. Fez1/lzts1 alterations in gastric carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2001; 7(6):1546-1552.
17. Vecchione A, Ishii H, Baldassarre G, Bassi P, Trapasso F, Alder H, Pagano F, Gomella LG, Croce CM and Baffa R. FEZ1/LZTS1 is down-regulated in high-grade bladder cancer, and its restoration suppresses tumorigenicity in transitional cell carcinoma cells. The American journal of pathology. 2002; 160(4):1345-1352.
18. Ono K, Uzawa K, Nakatsuru M, Shiiba M, Mochida Y, Tada A, Bukawa H, Miyakawa A, Yokoe H and Tanzawa H. Down-regulation of FEZ1/LZTS1 gene with frequent loss of heterozygosity in oral squamous cell carcinomas. International journal of oncology. 2003; 23(2):297-302.
19. Vecchione A, Galetti TP, Gardiman M, Ishii H, Giarnieri E, Pagano F, Gomella LG, Croce CM and Baffa R. Collecting duct carcinoma of the kidney: an immunohistochemical study of 11 cases. BMC urology. 2004; 4:11.
20. Toyooka S, Fukuyama Y, Wistuba, II, Tockman MS, Minna JD and Gazdar AF. Differential expression of FEZ1/LZTS1 gene in lung cancers and their cell cultures. Clinical cancer research: an official journal of the American Association for Cancer Research. 2002; 8(7):2292-2297.
21. Nonaka D, Fabbri A, Roz L, Mariani L, Vecchione A, Moore GW, Tavecchio L, Croce CM and Sozzi G. Reduced FEZ1/LZTS1 expression and outcome prediction in lung cancer. Cancer research. 2005; 65(4):1207-1212.
22. Chen L, Zhu Z, Sun X, Dong XY, Wei J, Gu F, Sun YL, Zhou J, Dong JT and Fu L. Down-regulation of tumor suppressor gene FEZ1/LZTS1 in breast carcinoma involves promoter methylation and associates with metastasis. Breast cancer research and treatment. 2009; 116(3):471-478.
23. Baffa R, Fassan M, Sevignani C, Vecchione A, Ishii H, Giarnieri E, Iozzo RV, Gomella LG and Croce CM. Fez1/Lzts1-deficient mice are more susceptible to N-butyl-N-(4-hydroxybutil) nitrosamine (BBN) carcinogenesis. Carcinogenesis. 2008; 29(4):846-848.
24. Vecchione A, Baldassarre G, Ishii H, Nicoloso MS, Belletti B, Petrocca F, Zanesi N, Fong LY, Battista S, Guarnieri D, Baffa R, Alder H, Farber JL, Donovan PJ and Croce CM. Fez1/Lzts1 absence impairs Cdk1/Cdc25C interaction during mitosis and predisposes mice to cancer development. Cancer cell. 2007; 11(3):275-289.
25. Ishii H, Vecchione A, Murakumo Y, Baldassarre G, Numata S, Trapasso F, Alder H, Baffa R and Croce CM. FEZ1/LZTS1 gene at 8p22 suppresses cancer cell growth and regulates mitosis. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98(18):10374-10379.
26. Giordano SH, Lin YL, Kuo YF, Hortobagyi GN and Goodwin JS. Decline in the use of anthracyclines for breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2012; 30(18):2232-2239.
27. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418):61-70.
28. Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, Wolf D, et al. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast cancer research and treatment. 2012; 132(3):1049-1062.
29. Longley DB and Johnston PG. Molecular mechanisms of drug resistance. The Journal of pathology. 2005; 205(2):275-292.
30. Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacon JI, Ferrer-Lozano J, et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA: the journal of the American Medical Association. 2011; 305(18):1873-1881.
31. Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ and Berry DA. HER2 and response to paclitaxel in node-positive breast cancer. The New England journal of medicine. 2007; 357(15):1496-1506.
32. Wang XX, Zhu Z, Su D, Lei T, Wu X, Fan Y, Li X, Zhao J, Fu L, Dong JT and Fu L. Down-regulation of leucine zipper putative tumor suppressor 1 is associated with poor prognosis, increased cell motility and invasion, and epithelial-to-mesenchymal transition characteristics in human breast carcinoma. Human pathology. 2011; 42(10):1410-1419.
33. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia (New York, NY). 2004; 6(1):1-6.